Market Overview

UPDATE: Dawson James Initiates Affymax at Market Outperform on Momentum


Dawson James initiated coverage on Affymax (NASDAQ: AFFY) with a Market Outperform rating and a $32 price target.

Dawson James commented, "Commercialization of new products is always tricky, especially in the current environment; however, we believe Omontys is an ideal product for the dialysis market given the new “bundled” pricing structure. … In addition, the receipt of a permanent “J code” (taking effect January 1, 2013) from the Centers for Medicare and Medicaid Services (CMS) should help lubricate reimbursement conditions and persuade any hold-outs to make the conversion from Epogen to Omontys. As sales growth momentum continues, so also should share price appreciation."

Affymax closed at $23.55 on Monday.

Latest Ratings for AFFY

Mar 2013DowngradesSell
Feb 2013DowngradesBuyNeutral
Feb 2013DowngradesMarket OutperformMarket Underperform

View More Analyst Ratings for AFFY
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (AFFY)

View Comments and Join the Discussion!

Latest Ratings

MEGJP MorganUpgrades7.0
SRCMorgan StanleyMaintains56.0
RNGBank of AmericaReiterates198.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Dawson James Initiates Spectrum Pharmaceuticals at Market Outperform on Share Weakness

UPDATE: Dawson James Initiates Astex Pharmaceuticals at Market Outperform